Hemangiomas and angiosarcomas of the breast: Diagnostic utility of cell cycle markers with emphasis on Ki-67

Archives of Pathology and Laboratory Medicine

Volumn 131, Issue 4, 2007, Pages 538-544

  Shin, Sandra J ^a   Lesser, Martin ^b   Rosen, Paul Peter ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN D1; KI 67 ANTIGEN; PROTEIN P27; S PHASE KINASE ASSOCIATED PROTEIN 2;

ADULT; ANGIOSARCOMA; ARTICLE; BREAST SARCOMA; CELL CYCLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CORRELATION ANALYSIS; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; FEMALE; HEMANGIOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MALE; PROGNOSIS; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; VASCULAR TUMOR;

BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CELL CYCLE; CYCLIN D1; DIAGNOSIS, DIFFERENTIAL; FEMALE; HEMANGIOMA; HEMANGIOSARCOMA; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; PROLIFERATING CELL NUCLEAR ANTIGEN; S-PHASE KINASE-ASSOCIATED PROTEINS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 34147179955     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Donnell RM, Rosen PP, Lieberman PH, et al. Angiosarcoma and other vasular tumors of the breast: pathologic analysis as a guide to prognosis. Am J Surg Pathol. 1981;5:629-642.
2. Rosen PP, Kimmel M, Ernsberger D. Mammary angiosarcoma: the prognostic significance of tumor differentiation. Cancer. 1988;62:2145-2151.
3. Yang XJ, McEntee M, Epstein JI. Distinction of basaloid carcinoma of the prostate from benign basal cell lesions by using immunohistochemistry for bcl-2 and Ki-67. Hum Pathol. 1998;28:1447-1450.
4. Hoda SA, Cranor ML, Rosen PP. Hemangiomas of the breast with atypical histological features: further analysis of histological subtypes confirming their benign character. Am J Surg Pathol. 1992;16:553-560.
5. Jozefczyk MA, Rosen PP. Vascular tumors of the breast, II: perilobular hemangiomas and hemangiomas. Am J Surg Pathol. 1985;9:491-503.
6. Rosen PP. Vascular tumors of the breast, III: angiomatosis. Am J Surg Pathol. 1985;9:652-655.
7. Rosen PP. Vascular tumors of the breast, V: non-parenchymal hemangiomas of mammary subcutaneous tissue. Am J Surg Pathol. 1985;9:723-729.
8. Liberman L, Dershaw DD, Kaufman RJ, et al. Angiosarcoma of the breast. Radiology. 1992;183:649-654.
9. Rosen PP. Sarcoma. In: Rosen's Breast Pathology. 2nd ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001:813-862.
10. Engellau J, Persson A, Bendahl P, et al. Expression profiling using tissue microarray in 211 malignant fibrous histiocytomas confirms the prognostic value of Ki-67. Virchows Arch. 2004;445:224-230.
11. Wolfsberger S, Fischer I, Höftberger R, et al. Ki-67 immunolabeling index is an accurate predictor of outcome in patients with intracranial ependymoma. Am J Surg Pathol. 2004;28:914-920.
12. Lum CA, Binder SW. Proliferative characterization of basal-cell carcinoma and trichoepithelioma in small biopsy specimens. J Cutan Pathol. 2004;31:550-554.
13. Mayerhofer K, Lozanov P, Bodner K, et al. Ki-67 expression in patients with uterine leiomyomas, uterine smooth muscle tumors of uncertain malignant potential (STUMP) and uterine leiomyosarcomas (LMS). Acta Obstet Gynecol Scand 2004;83:1085-1088.
14. Oda Y, Takahira T, Kawaguchi K, et al. Low-grade fibromyxoid sarcoma versus low-grade myxofibrosarcoma in the extremities and trunk: a comparison of clinicopathological and immunohistochemical features. Histopathology. 2004;45:29-38.
15. Vang R, Barner R, Wheeler DT, et al. Immunohistochemical staining for Ki-67 and p53 helps distinguish endometrial arias-stella reaction from high-grade carcinoma, including clear cell carcinoma, Int J Gynecol Pathol. 2004;23:223-233.
16. Vargas MP, Vargas HI, Kleiner DE, et al. Adrenocortical neoplasms: role of prognostic markers MIB-1, p53, and Rb. Am J Surg Pathol. 1997;21:556-562.
17. Vollmer RT. Use of Bayes rule and MIB-1 proliferation index to discriminate Spitz nevus from malignant melanoma. Am J Clin Pathol. 2004;122:499-505.
18. Dyduch G, Okoń K. Proliferation and apoptosis within the oral mucosa "hemangiomas." Pol J Pathol. 2000;51(2):93-96.
19. Dyduch G, Okoń K, Mierzyński W. Benign vascular proliferations: an immunohistochemical and comparative study. Pol J Pathol. 2004;55(2):59-64.
20. Alkarain A, Jordan R, Slingerland J. p27 deregulation in breast cancer: prognostic significance and implications for therapy. J Mammary Gland Biol Neoplasia. 2004;9:67-80.
21. Kip1 and of its ubiquitin ligase subunit skp2 in colorectal carcinomas. Cancer. 2001;91:1745-1751.
22. Langner C, von Wasielewski R, Ratschek M, et al. Biological significance of p27 and Skp2 expression in renal cell carcinoma: a systemic analysis of primary and metastatic tumor tissues using a tissue microarray technique. Virchows Arch. 2004;445:631-636.
23. Sanada T, Yokoi S, Arii S, et al. Skp2 overexpression is a p27-independent predictor of poor prognosis in patients with biliary tract cancers. Cancer Sci. 2004;95:969-976.
24. Swanton C. Cell-cycle targeted therapies. Lancet. 2004;5:27-36.
25. Kim SH, Lewis JJ, Brennan MF, et al. Overexpression of cyclin D1 is associated with poor prognosis in extremity soft-tissue sarcomas. Clin Can Res. 1998;4:2377-2382.
26. 1-S modulators (p53, p21Waf1, p27Kip1, cyclin D1, and cyclin D3), proliferation index, and clinicopathologic parameters. Am J Clin Pathol. 2004;122:444-452.